![](https://endpts.com/wp-content/uploads/2024/05/Chris-Viehbacher-Biogen-Financial-Times-Summit-feature.jpg)
Biogen CEO Chris Viehbacher at the Financial Times' US Pharma and Biotech Summit, held in partnership with Endpoints News (Sarah Merians Photography for Endpoints News)
Biogen makes $1.15B buy for ARCH's HI-Bio to expand immunology pipeline
Biogen is further expanding beyond its neuroscience roots and dipping more into immunology with a $1.15 billion upfront acquisition of Human Immunology Biosciences, or HI …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.